Archives

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system
Market Updates

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgeryin the U.S. presented as a late-breaker at the American Urologic Associati...

  • April 26, 2025 11:20 AM PDT
  • EODHD
Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings
Market Updates

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings

Amazon, Apple, Meta and Microsoft will need to address tariffs on earnings calls next week. Tech executives are sounding alarms. Continue Reading View Comments

  • April 26, 2025 11:14 AM PDT
  • EODHD
Prediction: Rivian Will Soar in 2026 for 1 Simple Reason
Market Updates

Prediction: Rivian Will Soar in 2026 for 1 Simple Reason

Prediction: Rivian Will Soar in 2026 for 1 Simple Reason

  • April 26, 2025 11:12 AM PDT
  • EODHD
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Market Updates

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of...

  • April 26, 2025 10:30 AM PDT
  • EODHD
Akeso survival data for ivonescimab misses expectations, STAT says
Market Updates

Akeso survival data for ivonescimab misses expectations, STAT says

While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jon...

  • April 26, 2025 09:50 AM PDT
  • EODHD
Biohaven share price undervaluing pipeline potential, says RBC Capital
Market Updates

Biohaven share price undervaluing pipeline potential, says RBC Capital

RBC Capital points out that notes released by the European Medicines Agency’s CHMP indicated that Biohaven (BHVN) had withdrawn the application for troriluzole in spinocerebellar ataxia. Investor sent...

  • April 26, 2025 09:10 AM PDT
  • EODHD
Bob Bakish was ousted by Paramount after clashing with Shari Redstone and he still got rewarded with a $69.3 million golden parachute
Market Updates

Bob Bakish was ousted by Paramount after clashing with Shari Redstone and he still got rewarded with a $69.3 million golden parachute

Bob Bakish, who was ousted as CEO of Paramount in last April, received $69.3 million as part of his severance compensation. The package was revealed in a Paramount filing disclosed by the SEC on Frida...

  • April 26, 2025 08:23 AM PDT
  • EODHD
Tractor Supply price target lowered to $60 from $67 at Telsey Advisory
Market Updates

Tractor Supply price target lowered to $60 from $67 at Telsey Advisory

Telsey Advisory lowered the firm’s price target on Tractor Supply (TSCO) to $60 from $67 and keeps an Outperform rating on the shares. The company continues to see further market share gains and stron...

  • April 26, 2025 08:01 AM PDT
  • EODHD
Trump 2.0 Era Brings Flurry of Crypto Deals
Market Updates

Trump 2.0 Era Brings Flurry of Crypto Deals

President Trump’s embrace of digital currencies has unleashed a flurry of crypto deals, with companies seeking to capitalize on lighter U.S. regulation and what they hope will be growing mainstream in...

  • April 26, 2025 08:00 AM PDT
  • EODHD